Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report

BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) inhibitor that is currently the first-line treatment for metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) due to its favorable efficacy and tolerability profile compared to previous generations of EGFR in...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Karishma, Hsu, Kristie Y., Lou, Kevin, Soni, Krishan, Lee, Yoo Jin, Mulvey, Claire K., Baik, Alan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617075/
https://www.ncbi.nlm.nih.gov/pubmed/37908018
http://dx.doi.org/10.1186/s40959-023-00190-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617075/
https://www.ncbi.nlm.nih.gov/pubmed/37908018
http://dx.doi.org/10.1186/s40959-023-00190-1

Ejemplares similares